Literature DB >> 19216844

The chemokine receptors CXCR4 and CXCR3 in cancer.

Amy M Fulton1.   

Abstract

Chemokines comprise a superfamily of at least 46 cytokines that were initially described based on their ability to bind to 18 to 22 G protein-coupled receptors to induce the directed migration of leukocytes to sites of inflammation or injury. In addition to mediating cellular migration, chemokine/chemokine receptor pairs have been shown to affect many cellular functions, including survival, adhesion, invasion, and proliferation, and to regulate circulating chemokine levels. Most malignancies also express one or more chemokine receptors. Early studies established a role for CXCR4 and CXCR7 in mediating breast cancer metastasis, but other chemokine receptors, including CXCR3, now are implicated in several malignancies as biomarkers of tumor behavior as well as potential therapeutic targets. This review summarizes our current understanding regarding the contribution of CXCR4 and CXCR3 to tumor behavior and how receptor expression is regulated, transduces intracellular signals, and contributes at the molecular level to tumor behavior. It also describes recent therapeutic approaches that target these receptors or their ligands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19216844     DOI: 10.1007/s11912-009-0019-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  38 in total

1.  Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.

Authors:  Dipak Datta; Jesse A Flaxenburg; Sreenivas Laxmanan; Christopher Geehan; Martin Grimm; Ana Maria Waaga-Gasser; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

2.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.

Authors:  Tonya C Walser; Salah Rifat; Xinrong Ma; Namita Kundu; Chris Ward; Olga Goloubeva; Michael G Johnson; Julio C Medina; Tassie L Collins; Amy M Fulton
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

3.  Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma.

Authors:  Russell Dorsey; Namita Kundu; Qingyuan Yang; Charles S Tannenbaum; Hui Sun; Thomas A Hamilton; Amy M Fulton
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

4.  Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145.

Authors:  Takuya Akashi; Keiichi Koizumi; Osamu Nagakawa; Hideki Fuse; Ikuo Saiki
Journal:  Oncol Rep       Date:  2006-10       Impact factor: 3.906

5.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

6.  The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines.

Authors:  Lilach Goldberg-Bittman; Eran Neumark; Orit Sagi-Assif; Elina Azenshtein; Tsipi Meshel; Isaac P Witz; Adit Ben-Baruch
Journal:  Immunol Lett       Date:  2004-03-29       Impact factor: 3.685

7.  Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.

Authors:  David Zagzag; Yevgeniy Lukyanov; Li Lan; M Aktar Ali; Mine Esencay; Olga Mendez; Herman Yee; Evelyn B Voura; Elizabeth W Newcomb
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

Review 8.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

9.  CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Authors:  C Monteagudo; J M Martin; E Jorda; A Llombart-Bosch
Journal:  J Clin Pathol       Date:  2006-03-07       Impact factor: 3.411

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  50 in total

1.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

2.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

Review 3.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

4.  Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Authors:  Stephen R Goding; Kyle A Wilson; Ying Xie; Kristina M Harris; Aparna Baxi; Akgul Akpinarli; Amy Fulton; Koji Tamada; Scott E Strome; Paul Andrew Antony
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

5.  The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis.

Authors:  Mingzhi Han; Shunzeng Lv; Ya Zhang; Ruiyang Yi; Bin Huang; Hanhui Fu; Ruixiang Bian; Xingang Li
Journal:  Tumour Biol       Date:  2014-01-25

6.  Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.

Authors:  Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

7.  LIM and SH3 protein-1 modulates CXCR2-mediated cell migration.

Authors:  Dayanidhi Raman; Jiqing Sai; Nicole F Neel; Catherine S Chew; Ann Richmond
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

8.  Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.

Authors:  Mikhail A Zhukovsky; Stéphane Basmaciogullari; Beatriz Pacheco; Liping Wang; Navid Madani; Hillel Haim; Joseph Sodroski
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma.

Authors:  Zhen Liu; Da-Xin Sun; Xu-Yong Teng; Wei-Xue Xu; Xiang-Peng Meng; Bao-Sheng Wang
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

10.  Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity.

Authors:  Teshome L Aboye; Helen Ha; Subhabrata Majumder; Frauke Christ; Zeger Debyser; Alexander Shekhtman; Nouri Neamati; Julio A Camarero
Journal:  J Med Chem       Date:  2012-11-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.